Assembly Biosciences (ASMB) Projected to Post Quarterly Earnings on Thursday
by Jessica Moore · The Cerbat GemAssembly Biosciences (NASDAQ:ASMB – Get Free Report) is expected to be issuing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $9.2660 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.
Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, topping the consensus estimate of ($0.51) by $2.99. The company had revenue of $42.47 million for the quarter, compared to analyst estimates of $7.42 million. Assembly Biosciences had a negative return on equity of 5.63% and a negative net margin of 8.47%. On average, analysts expect Assembly Biosciences to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Assembly Biosciences Trading Up 1.6%
NASDAQ:ASMB opened at $27.82 on Tuesday. The firm has a market cap of $442.06 million, a P/E ratio of -37.59 and a beta of 1.08. The stock’s 50 day simple moving average is $28.60 and its 200-day simple moving average is $30.52. Assembly Biosciences has a 12-month low of $11.64 and a 12-month high of $39.71.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Virtus Investment Advisers LLC acquired a new position in Assembly Biosciences during the fourth quarter worth $251,000. Susquehanna Portfolio Strategies LLC acquired a new position in Assembly Biosciences during the fourth quarter worth $473,000. Superstring Capital Management LP acquired a new position in Assembly Biosciences during the fourth quarter worth $2,220,000. Millennium Management LLC grew its holdings in Assembly Biosciences by 354.6% during the fourth quarter. Millennium Management LLC now owns 98,221 shares of the biopharmaceutical company’s stock worth $3,340,000 after acquiring an additional 76,613 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in Assembly Biosciences by 11.3% during the fourth quarter. Janus Henderson Group PLC now owns 837,925 shares of the biopharmaceutical company’s stock worth $28,540,000 after acquiring an additional 85,299 shares during the period. Institutional investors and hedge funds own 19.92% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on ASMB shares. Wall Street Zen raised Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, March 29th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Monday, April 20th. Finally, Guggenheim boosted their target price on Assembly Biosciences from $39.00 to $43.00 and gave the company a “buy” rating in a report on Monday, April 6th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.75.
Get Our Latest Report on Assembly Biosciences
About Assembly Biosciences
Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.
The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.